Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%

Sensei Biotherapeutics, Inc.

Discontinued solnerstotug development; Board considering sale, merger, or wind-down.
Workforce cut ~65% to preserve cash; small team retained for strategic review.
Cash $25.0M as of Sep 30, 2025, down from $41.3M at Dec 31, 2024.
Q3 2025 net loss $4.6M (vs $7.3M YoY); R&D $2.5M (vs $4.6M YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.